Market Cap | 1.65B | P/E | - | EPS this Y | 214.30% | Ern Qtrly Grth | 119.40% |
Income | -3.18M | Forward P/E | 432.88 | EPS next Y | 512.50% | 50D Avg Chg | -3.00% |
Sales | 197.52M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 17.00% |
Dividend | N/A | Price/Book | 8.28 | EPS next 5Y | - | 52W High Chg | -13.00% |
Recommedations | 1.30 | Quick Ratio | 3.67 | Shares Outstanding | 48.38M | 52W Low Chg | 100.00% |
Insider Own | 0.84% | ROA | -1.29% | Shares Float | 44.66M | Beta | 1.73 |
Inst Own | 112.40% | ROE | -1.52% | Shares Shorted/Prior | 4.53M/2.37M | Price | 34.63 |
Gross Margin | 68.64% | Profit Margin | -1.61% | Avg. Volume | 350,367 | Target Price | 53.90 |
Oper. Margin | 19.59% | Earnings Date | May 8 | Volume | 623,823 | Change | -1.40% |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Truist Securities | Buy | Mar 26, 24 |
Truist Securities | Buy | Mar 1, 24 |
HC Wainwright & Co. | Buy | Mar 1, 24 |
Truist Securities | Buy | Jan 25, 24 |
HC Wainwright & Co. | Buy | Jan 16, 24 |
Truist Securities | Hold | Nov 9, 23 |
Leerink Partners | Outperform | Oct 16, 23 |
Truist Securities | Hold | Sep 21, 23 |
Stephens & Co. | Overweight | Sep 21, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
ZERBE ROBERT L MD | Director Director | Jul 14 | Sell | 38.84 | 1,000 | 38,840 | 33,395 | 07/17/23 |
Colangelo Dominick | President and CEO President and CEO | Jan 10 | Sell | 27.13 | 39,938 | 1,083,518 | 157,066 | 01/12/23 |
Colangelo Dominick | President and CEO President and CEO | Jan 10 | Option | 25.8 | 39,938 | 1,030,400 | 197,004 | 01/12/23 |
Hopper Jonathan Mark | Chief Medical Office.. Chief Medical Officer | Dec 20 | Option | 12.85 | 20,000 | 257,000 | 49,428 | 12/22/21 |
Hopper Jonathan Mark | Chief Medical Office.. Chief Medical Officer | Dec 20 | Sell | 40.07 | 15,881 | 636,352 | 43,547 | 12/22/21 |
Hopper Jonathan Mark | Chief Medical Office.. Chief Medical Officer | Dec 23 | Option | 10.95 | 43,264 | 473,741 | 35,069 | 12/23/20 |
Hopper Jonathan Mark | Chief Medical Office.. Chief Medical Officer | Dec 23 | Sell | 26.5 | 24,235 | 642,228 | 23,360 | 12/23/20 |
ZERBE ROBERT L MD | Director Director | Nov 24 | Option | 3.25 | 30,000 | 97,500 | 49,295 | 11/24/20 |
ZERBE ROBERT L MD | Director Director | Nov 24 | Sell | 23.55 | 17,500 | 412,125 | 31,795 | 11/24/20 |